title: Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab.
authors.affiliation: Genentech, Inc, South San Francisco, Calif.
authors.forename: Tracy L
authors.initials: TL
authors.lastname: Staton
authors.affiliation: Genentech, Inc, South San Francisco, Calif.
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Arron
authors.affiliation: Genentech, Inc, South San Francisco, Calif.
authors.forename: Julie
authors.initials: J
authors.lastname: Olsson
authors.affiliation: Genentech, Inc, South San Francisco, Calif.
authors.forename: Cécile T J
authors.initials: CTJ
authors.lastname: Holweg
authors.affiliation: Genentech, Inc, South San Francisco, Calif.
authors.forename: John G
authors.initials: JG
authors.lastname: Matthews
authors.affiliation: Genentech, Inc, South San Francisco, Calif. Electronic address: choy.david@gene.com.
authors.forename: David F
authors.initials: DF
authors.lastname: Choy
mesh_terms: D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology; D002452:Cell Count; D016207:Cytokines / Q000378:metabolism; D018450:Disease Progression; D004804:Eosinophils / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D010850:Picornaviridae Infections / Q000453:epidemiology*; D020545:Respiratory Mucosa / Q000502:physiology*; D012229:Rhinovirus / Q000276:immunology*; D012621:Seasons; D015398:Signal Transduction; D051193:Toll-Like Receptors / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D016207:Cytokines; D051193:Toll-Like Receptors; C561806:lebrikizumab